CDIO vs. SAI, ARIZ, MCAG, VNRX, ABIO, ICCC, AWH, OCX, TRIB, and BMRA
Should you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include SAI.TECH Global (SAI), Arisz Acquisition (ARIZ), Mountain Crest Acquisition Corp. V (MCAG), VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), Trinity Biotech (TRIB), and Biomerica (BMRA).
Cardio Diagnostics (NASDAQ:CDIO) and SAI.TECH Global (NASDAQ:SAI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
Cardio Diagnostics has a beta of 5.3, meaning that its stock price is 430% more volatile than the S&P 500. Comparatively, SAI.TECH Global has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.
SAI.TECH Global has higher revenue and earnings than Cardio Diagnostics.
8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 0.2% of SAI.TECH Global shares are owned by institutional investors. 30.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 1.4% of SAI.TECH Global shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
SAI.TECH Global has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -34,911.87%. SAI.TECH Global's return on equity of 0.00% beat Cardio Diagnostics' return on equity.
In the previous week, SAI.TECH Global had 4 more articles in the media than Cardio Diagnostics. MarketBeat recorded 6 mentions for SAI.TECH Global and 2 mentions for Cardio Diagnostics. SAI.TECH Global's average media sentiment score of 0.53 beat Cardio Diagnostics' score of 0.30 indicating that SAI.TECH Global is being referred to more favorably in the news media.
Cardio Diagnostics presently has a consensus price target of $1.35, suggesting a potential upside of 94.89%. Given Cardio Diagnostics' higher possible upside, equities analysts clearly believe Cardio Diagnostics is more favorable than SAI.TECH Global.
Cardio Diagnostics received 2 more outperform votes than SAI.TECH Global when rated by MarketBeat users.
Summary
Cardio Diagnostics and SAI.TECH Global tied by winning 7 of the 14 factors compared between the two stocks.
Get Cardio Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardio Diagnostics Competitors List
Related Companies and Tools
